N@N

OPKO HEALTH INCORPORATION (AMEX:OPK), Up By 5.98% ($0.22) From $3.680 After BUYINS.NET Report Predicted Stock Would Go Up Due T

^{Published on 2011-08-12 05:29:00 - WOPRAI}
 

August 12, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, August 10th 2011 stating that OPKO HEALTH INCORPORATION (AMEX:OPK) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=opk&id=184999

At the time this story was written, OPKO HEALTH INCORPORATION (AMEX:OPK) is Up By $0.22 (5.98%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

OPKO HEALTH INCORPORATION (AMEX:OPK) - OPKO Health, Inc., a specialty healthcare company, engages in the discovery, development, and commercialization of pharmaceutical products, medical devices, vaccines, diagnostic technologies, and imaging systems for treatment and management of ophthalmic diseases. Its product candidates include Rolapitant, which is in Phase III clinical trial to treat emesis; Bevasiranib that is in Phase III clinical trials for the treatment of wet age-related macular degeneration (Wet AMD); Doxovir, which is in Phase II clinical trials for viral conjunctivitis; SCH 900978 that is in Phase II clinical trials for emesis; and ACU-HHY-011 to treat wet AMD. The companys products under pre-clinical stage of development comprise Alzheimers test for Alzheimers diagnostic; flu vaccine for the treatment of pan-influenza; and OPK-HVB-004 and OPK-HVB-010 to treat wet AMD/diabetic retinopathy/diabetic macular edema. It also offers ophthalmic diagnostic systems and instrumentation products, including spectral OCT SLO combination imaging system and ultrasound products; and develops Aquashunt, a shunt used in the treatment of refractory open angle glaucoma. The company sells ophthalmic instruments, imaging products, and other medical devices to various eye care practitioners, including retinal and glaucoma specialists, ophthalmologists, optometrists, retail optometry chain outlets, teaching institutions, and military hospitals. It has strategic license agreements with the University of Texas, Southwestern Medical Center, Academia Sinica, the University of Pennsylvania, the University of Florida Research Foundation, and Redox Pharmaceuticals. The company was founded in 2006 and is headquartered in Miami, Florida.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net